NLA 2022 to feature new statin intolerance guidelines, award-winning abstracts, more
Click Here to Manage Email Alerts
The National Lipid Association Scientific Sessions will be held today to Saturday and will spotlight statements on statin-associated muscle symptoms, sessions focusing on translational and implementation science and more.
Healio spoke with National Lipid Association (NLA) President Joseph Saseen, PharmD, associate dean for clinical affairs, professor in the department of clinical pharmacy and department of family medicine at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, about some of the topics in the spotlight this year and what attendees can hope to garner from the sessions.
“It’s the right time [for NLA]. Even though we still have our guard up and [COVID-19] precautions in place, such as requiring vaccination, we’re all excited and enthused to have a face-to-face live annual meeting again,” Saseen told Healio. “Our desire with our scientific sessions to have content that applies to our diverse membership population, which includes clinical pharmacists, dietitians, nurses, physicians, physician assistants and clinical scientists ... and a lot of our sessions exude that broad perspective.
“Our opening session is going to be about evaluating the evidence that support nonstatin therapy in patients that have statin-associated muscle symptoms,” Saseen said. “We’re going to use a fun approach where we have four people presenting evidence with four different treatment options, and then we are going to globally discuss a case presentation and use audience polling and panel discussion to spice it up.”
The NLA opening session, “Expert Analysis: Evidence Supporting Non-Statin Therapies in a Patient with Statin Associated Muscle Symptoms (SAMS),” will take place today at 4 p.m. MST.
“Something else you may not see at a lot of sessions is this session about translating evidence into practice or translational or implementation science, on Friday morning,” Saseen told Healio. “It goes over things such as effective communication strategies, optimizing your electronic health record and using novel approaches to improve the care, not just of one individual patient, but your patient population.”
On Saturday, three late-breaking clinical trials will be presented:
- Apolipoprotein B and Lipoprotein(a) across Atherosclerotic Cardiovascular Disease Risk Categories Among Hispanic/Latino Individuals Residing in the United States: Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) – presented by Parag H. Joshi, MD, MHS;
- Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins – Results from the ROSE Clinical Trial – presented by Michael H. Davidson, MD, FACC, FNLA; and
- Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction: REDUCE-IT PRIOR MI – presented by Prakriti Gaba, MD.
“We also have our scientific abstracts where we hopefully have some cutting-edge science presented, but we do have a lot of our other sessions,” Saseen told Healio. “We have sessions that are for the clinicians, such as different viewpoints about treatment options; session about drug misadventures; we have a session on diversity, equity and inclusion (DEI) to give our audience members some tips on how to improve any DEI efforts that they have, whether it be a training program or delivering more DEI-focused wellness care.”
Among nearly 40 scientific abstracts to be presented during NLA, the following four will be oral presentations:
- Universal Screening for Familial Hypercholesterolemia in Two Populations – presented by Urh Groselj, MD;
- A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy – presented by Loba Alam, MD;
- An Unsolved Case: FH or Sitosterolemia? – presented by Juliette Logan, MD, the first-place Young Investigator Award Winner and the first place oral presenter; and
- Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia – presented by Amanda Guerin, BSc, the Donald Hunninghake, MD, Familial Hypercholesterolemia Abstract Award Winner
“Maybe the cherry on the top is that we’re going to have a session that’s called scientific statements, and we’re going to be releasing our scientific statement on statin intolerance, which we’re really excited about. It’ll be available as an early release in the Journal of Clinical Lipidology that morning,” Saseen told Healio.
The statement on statin intolerance will be presented by Kevin C. Maki, PhD, CLS, FNLA, the incoming president of the NLA, on Saturday at 9 a.m. MST.
Also to be presented is a scientific statement, titled “Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.” This statement will be presented by P. Barton Duell, MD, FNLA, on Saturday at 9:30 a.m. MST.
Healio is a media partner of the NLA Scientific Sessions. The Healio team will provide coverage from the meeting, including reports on the sessions above and more. Follow along at this link and on Twitter at @CardiologyToday. For more information on NLA, visit www.lipid.org/meetings/sessions/home.
Collapse
Healio Interviews
Click Here to Manage Email Alerts